BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 113.51 USD 0.38% Market Closed
Market Cap: 27.4B USD
Have any thoughts about
BioNTech SE?
Write Note

Net Margin
BioNTech SE

-15.4%
Current
36%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-15.4%
=
Net Income
-466.9m
/
Revenue
3B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DE
BioNTech SE
NASDAQ:BNTX
27.2B USD
-15%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country DE
Market Cap 27.2B USD
Net Margin
-15%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 315.2B USD
Net Margin
9%
Country US
Market Cap 141.9B USD
Net Margin
13%
Country US
Market Cap 116.4B USD
Net Margin
0%
Country US
Market Cap 104.5B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

BioNTech SE
Glance View

Market Cap
27.2B USD
Industry
Biotechnology

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
32.68 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-15.4%
=
Net Income
-466.9m
/
Revenue
3B
What is the Net Margin of BioNTech SE?

Based on BioNTech SE's most recent financial statements, the company has Net Margin of -15.4%.